



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/CAT/86491/2026
Human Medicines Division

Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 15-17 April 2026

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

15 April 2026, 14:00 – 18:30

16 April 2026, 09:00 – 18:30

17 April 2026, 09:00 – 13:00

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.1.1.	Onasemnogene abeparvovec - Orphan - EMEA/H/C/006498.....	5
2.2.	Oral explanations	5
2.3.	Day 180 list of outstanding issues	5
2.4.	Day 120 list of questions	5
2.5.	Day 80 assessment reports	6
2.6.	Update on ongoing initial applications.....	6
2.6.1.	Zopapogene Imadenovec - Orphan - EMEA/H/C/006508.....	6
2.7.	New applications	6
2.7.1.	Lunsotogene parvec - Orphan - H0006802.....	6
2.8.	Withdrawal of initial marketing authorisation application	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	6
2.10.	GMP and GCP inspections requests.....	6
2.11.	Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	6
2.11.1.	Abecma - Idecabtagene vicleucel - Orphan - EMA/VR/0000327582	6
2.11.2.	Breyanzi - Lisocabtagene maraleucel - EMA/VR/0000327431	7
2.11.3.	CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000327548	7
2.11.4.	Kymriah - Tisagenlecleucel - Orphan - EMA/VR/0000302038.....	7
2.11.5.	Tecartus / Yescarta - Brexucabtagene autoleucel / Axicabtagene ciloleucel - Orphan - EMA/VR/0000308229	7
2.12.	Extension applications.....	8
2.13.	Other Post-Authorisation Activities	8
2.13.1.	Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000328242.....	8
2.13.2.	Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000328232.....	8
2.13.3.	Ebvallo - Tabelecleucel - Orphan - EMA/PAM/0000326954	8
2.14.	Companion diagnostics - initial consultation	8
2.15.	Companion diagnostics – Follow-up consultation	8
3.	Certification of ATMPs	9
3.1.	Opinion.....	9

3.2.	Day 60 Evaluation Reports.....	9
3.3.	New Applications.....	9
4.	Scientific Recommendation on Classification of ATMPs	9
4.1.	New requests – Appointment of CAT Coordinator	9
4.1.1.	Autologous venous graft.....	9
4.1.2.	Human type I collagen, lyophilised.....	9
4.1.3.	Autologous platelet-rich plasma (PRP) combined with mechanically processed autologous adipose tissue (nanofat)	10
4.1.4.	Allogeneic human umbilical cord-derived mesenchymal stromal cells	10
4.1.5.	Adeno-associated virus serotype rh.74 viral vector encoding the human B-cell Lymphoma 2 (BCL-2)-associated athanogene 3 (BAG3) gene (AAVrh.74-BAG3)	10
4.1.6.	Replication-competent, plaque-purified, attenuated mumps virus variant	10
4.2.	Day 30 ATMP scientific recommendation	10
4.2.1.	Recombinant chicken annexin V labelled inactivated autologous tumour cells.....	10
4.2.2.	Adenovirus type 5 vector expressing human granulocyte-macrophage colony-stimulating factor	10
4.2.3.	Autologous adipose-derived stromal vascular fraction	11
4.3.	Day 60 revised scientific recommendation (following list of questions)	11
4.4.	Follow-up and guidance.....	11
4.4.1.	Live attenuated viral vector vaccine based on SARS-COV-2 backbone, expressing human interferon beta COVID-19 prophylaxis	11
5.	Scientific Advice	11
5.1.	New requests - appointment of CAT Rapporteurs	11
5.1.1.	Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers	11
5.2.	Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs	12
5.3.	Finalisation of D70 procedures – feedback from the discussion meeting.....	12
6.	Pre-Authorisation Activities	12
6.1.	Paediatric investigation plans.....	12
6.2.	ITF briefing meetings in the field of ATMPs	12
6.2.1.	Overview of ITF meetings in 2025	12
6.3.	Priority Medicines (PRIME) – Eligibility requests.....	12
6.3.1.	Month 0 - Start of the procedure	12
6.3.2.	Month 1 – Discussion of eligibility	12
6.3.3.	Month 2 – Recommendation of eligibility.....	12
6.3.4.	Ongoing support.....	12
7.	Organisational, regulatory and methodological matters	13
7.1.	Mandate and organisation of the CAT	13
7.1.1.	CAT membership	13

7.1.2.	Nominated proxy	13
7.1.3.	CAT Strategic Review & Learning meeting (SRLM) under the Cypriot presidency.....	13
7.1.4.	CAT Strategic Review & Learning meeting (SRLM) under the Irish presidency.....	13
7.1.5.	Revised CAT Rules of Procedure	13
7.2.	Coordination with EMA Scientific Committees.....	13
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	13
7.4.	Cooperation with the EU regulatory network.....	13
7.4.1.	EDQM update for CAT April 2026	13
7.5.	Cooperation with international regulators.....	14
7.5.1.	ATMP cluster teleconference with US-FDA, Health Canada, PMDA (Japan) and Swissmedic	14
7.6.	CAT work plan	14
7.7.	Planning and reporting	14
7.8.	Others	14
8.	Any other business	14
8.1.	New reimbursement rules of expenses for delegates attending meetings	14
9.	Explanatory notes	15

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 15-17 April 2026. See April 2026 CAT minutes (to be published post May 2026 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 15-17 April 2026 meeting

1.3. Adoption of the minutes

CAT minutes for 18-20 March 2026 meeting

2. Evaluation of ATMPs

2.1. Opinions

2.1.1. Onasemnogene abeparvovec - Orphan - EMEA/H/C/006498

Novartis Europharm Limited; Treatment of 5q spinal muscular atrophy (SMA)

Scope: Opinion

Action: for adoption

List of outstanding issues adopted on 20.02.2026. List of questions adopted on 12.09.2025.

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

No items

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

2.6.1. Zopapogene Imadenovec - Orphan - EMEA/H/C/006508

FGK Representative Service GmbH; Treatment of respiratory papillomatosis in adults

Scope: List of questions

Action: for adoption

2.7. New applications

2.7.1. Lunsotogene parvec - Orphan - H0006802

Regeneron Ireland DAC; Treatment of patients with biallelic OTOF variant-associated hearing loss

Scope: Accelerated assessment, opinion

Action: for discussion

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Abecma - Idecabtagene vicleucel - Orphan - EMA/VR/0000327582

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Rune Kjeklen

Scope: Quality, request for supplementary information

Action: for adoption

2.11.2. Breyanzi - Lisocabtagene maraleucel - EMA/VR/0000327431

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli, PRAC Rapporteur: Dirk Mentzer

Scope: Clinical, request for supplementary information

Submission of the final report from study CA082-1105 listed as a condition in the Annex II of the Product Information (PI). This is a non-interventional study submitted to summarise the consistency of Breyanzi product batch quality data measured at the time of release and clinical outcomes in patients treated with Breyanzi in the post-marketing setting for relapsed/refractory large B-cell lymphoma (R/R LBCL) within the approved indications and dose range per the EU PI. The Annex II and the RMP version 10.0 are updated accordingly. In addition, the MAH took the opportunity to make a minor editorial update by removing some grey shading from Annex III.

Action: for adoption

2.11.3. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMA/VR/0000327548

Janssen Cilag International

Rapporteur: Attila Sebe

Scope: Quality

Action: for adoption

2.11.4. Kymriah - Tisagenlecleucel - Orphan - EMA/VR/0000302038

Novartis Europharm Limited

Rapporteur: Rune Kjekken

Scope: Quality, opinion

Action: for adoption

2.11.5. Tecartus / Yescarta - Brexucabtagene autoleucel / Axicabtagene ciloleucel - Orphan - EMA/VR/0000308229

Kite Pharma EU B.V.

Rapporteur: Attila Sebe, PRAC Rapporteur: Karin Erneholm

Scope: Clinical, opinion

Update of sections 4.2, 4.4, 4.5, 4.7 and 6.4 of the SmPC in order to modify the pre- and post-infusion monitoring recommendations and requirements related to the risk of CRS (cytokine release syndrome) and ICANS (immune effector cell-associated neurotoxicity syndrome) based on data from clinical trials, post-marketing experience and literature. The Package Leaflet is updated accordingly. The RMP version 7.1 has also been submitted. In

addition, Annex II has been updated accordingly. Furthermore, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to bring the PI in line with the latest QRD template version 10.4 and to implement editorial changes to the PI.

Action: for adoption

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000328242

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Attila Sebe

Scope: PAM

Action: for adoption

2.13.2. Casgevy - Exagamglogene autotemcel - Orphan - EMA/PAM/0000328232

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Attila Sebe

Scope: PAM

Action: for adoption

2.13.3. Ebvallo - Tabelecleucel - Orphan - EMA/PAM/0000326954

Pierre Fabre Medicament

Rapporteur: Attila Sebe

Scope: PAM

Action: for adoption

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Timetable:

-Start of the procedure:	20.04.2026
-EMA Coordinator's draft report:	30.04.2026
-CAT Coordinator's comments:	06.05.2026
-Revised scientific recommendation:	08.05.2026
-CAT's discussion of scientific recommendation:	13.05.2026

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Autologous venous graft

Reconstruction of the extrahepatic bile duct following circumferential resection during hepatobiliary surgery for malignant biliary tumours, including perihilar cholangiocarcinoma and other tumours involving the biliary confluence

Scope: ATMP scientific recommendation

Action: for nomination of CAT Coordinator

4.1.2. Human type I collagen, lyophilised

For intradermal injection into the facial dermis to correct dynamic wrinkles (crow's feet)

Scope: ATMP scientific recommendation

Action: for nomination of CAT Coordinator

4.1.3. Autologous platelet-rich plasma (PRP) combined with mechanically processed autologous adipose tissue (nanofat)

Treatment of refractory olfactory dysfunction

Scope: ATMP scientific recommendation

Action: for nomination of CAT Coordinator

4.1.4. Allogeneic human umbilical cord-derived mesenchymal stromal cells

Treatment of congenital diaphragmatic hernia

Scope: ATMP scientific recommendation

Action: for nomination of CAT Coordinator

4.1.5. Adeno-associated virus serotype rh.74 viral vector encoding the human B-cell Lymphoma 2 (BCL-2)-associated athanogene 3 (BAG3) gene (AAVrh.74-BAG3)

Treatment of BAG3-associated dilated cardiomyopathy (DCM)

Scope: ATMP scientific recommendation

Action: for nomination of CAT Coordinator

4.1.6. Replication-competent, plaque-purified, attenuated mumps virus variant

Treatment of breast cancer

Scope: ATMP scientific recommendation

Action: for nomination of CAT Coordinator

4.2. Day 30 ATMP scientific recommendation

4.2.1. Recombinant chicken annexin V labelled inactivated autologous tumour cells

Treatment of solid tumours, especially renal cell carcinoma and breast cancer

Scope: ATMP scientific recommendation

Action: for adoption

4.2.2. Adenovirus type 5 vector expressing human granulocyte-macrophage colony-stimulating factor

Treatment of bladder cancer

Scope: ATMP scientific recommendation

Action: for adoption

4.2.3. Autologous adipose-derived stromal vascular fraction

Treatment of acute spinal cord injury

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Follow-up and guidance

4.4.1. Live attenuated viral vector vaccine based on SARS-COV-2 backbone, expressing human interferon beta COVID-19 prophylaxis

Scope: ATMP scientific recommendation

Action: for adoption

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	07-10.04.2026
- Appointment of CAT Peer Reviewers:	15-17.04.2026
- SAWP first reports:	27.04.2026
- CAT Peer Reviewer comments (NC & C):	30.04.2026
- CAT Peer Reviewer comments (Q):	06.05.2026
- Discussion at SAWP:	04-07.05.2026
- Discussion at CAT and feedback to SAWP:	11-13.05.2026

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

6.2.1. Overview of ITF meetings in 2025

Scope: Update

Action: for information

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start:	07-10.04.2026
SAWP recommendation:	07.05.2026
CAT recommendation:	13.05.2026
CHMP adoption of report and final recommendation:	21.05.2026

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

7.1.2. Nominated proxy

Action: for information

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Cypriot presidency

Scope: Preparation for the meeting

CAT: Rafaella Pontou

Action: for information

7.1.4. CAT Strategic Review & Learning meeting (SRLM) under the Irish presidency

Scope: Preparation for the meeting

CAT: Joseph deCoursey

Action: for information

7.1.5. Revised CAT Rules of Procedure

Scope: Working arrangements

Action: for adoption

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

7.4.1. EDQM update for CAT April 2026

CAT: Olga Kolaj-Robin

Scope: Adoption of the revised chapter 5.1.6 Alternative methods for control of

microbiological quality and news on the certified review of microbiological methods per the European Pharmacopoeia.

Action: for information

7.5. Cooperation with international regulators

7.5.1. ATMP cluster teleconference with US-FDA, Health Canada, PMDA (Japan) and Swissmedic

CAT: Ilona Reischl

Scope: Agenda of the ATMP cluster of 23.04.2025

Action: for information

7.6. CAT work plan

No items

7.7. Planning and reporting

No items

7.8. Others

No items

8. Any other business

8.1. New reimbursement rules of expenses for delegates attending meetings

Scope: Update on reimbursement rules for delegates

Action: for information

Date of next CAT meeting:

11-13 May 2026

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations in Committee CMD documents and in relation to EMA regulatory activities


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

GMP and GCP Inspections Issues (section 2.10)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Companion diagnostics (section 2.14. & 2.15.)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT.

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested

parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/